Latest Regulatory Review News

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Island Pharmaceuticals has inked a Master Service Agreement with Texas Biomedical Research Institute, enhancing its strategic position to advance Galidesivir through the FDA Animal Rule pathway. This partnership aligns with US government priorities on viral threats and sets the stage for a planned clinical program in early 2026.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Iris Cairns Property Pty Ltd has announced a delay in its takeover bid for Reef Casino Trust due to extended regulatory approval timelines, signaling a planned extension of the offer period beyond May 2026.

Northern Minerals has applied to defer its 2025 AGM as it awaits regulatory review over potential foreign investment breaches, underscoring heightened scrutiny on shareholder compliance.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

NuEnergy Gas Limited has completed drilling three wells and commenced initial gas sales at its Tanjung Enim PSC in Indonesia, marking a key step toward full-scale production. Regulatory approvals and commercial agreements are advancing, positioning the company for growth in the unconventional gas sector.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

Vintage Energy reported a 24% drop in quarterly sales revenue to $0.9 million alongside a 20% production decline, while initiating a Production Uplift Program targeting its Southern Flank gas fields and maintaining steady 2P reserves at 12.5 MMboe.

Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.

Pilbara Minerals has delivered a robust start to FY26, boosting lithium production and revenue while cutting unit costs at its Pilgangoora operation. The company also advances key growth projects amid a volatile lithium market.

Apiam Animal Health Limited has entered a binding agreement with Adamantem Capital Fund II for a $228.4 million acquisition via a scheme of arrangement, offering shareholders a significant premium and flexible cash or scrip consideration options.